(1/2): HHMI Investigator Alexander Rudensky & collaborators at @mskcancercenter.bsky.social have solved a 20-year mystery: Why are high levels of regulatory #Tcells linked to better survival in colorectal cancer, when they’re usually indicative of poor outcomes in most other cancers? bit.ly/3MGn9IY

Congratulations to Dr. Deb Schrag, a gastrointestinal medical oncologist and Chair of the Department of Medicine at MSK, on being elected as the 2027-28 President of the @ascocancer.bsky.social. Read more: bit.ly/3N8Nf7q

🚨This week in @natcomms.nature.com: We resolve an enduring enigma in T cell biology—how TCR binding to p/HLA triggers intracellular signaling. CryoEM in native environment reveals a 'jack-in-the-box' mechanism! Collab btw @rockefeller.edu @mskcancercenter.bsky.social rdcu.be/eUPPl

New research from #SABCS25 suggests acupuncture may help ease “chemo brain.” 🎧 Hear Dr. Jun Mao of @mskcancercenter.bsky.social#SABCS25explain more about the results of his research on our podcast today: https://bit.ly/4pE6TH1 #BreastCancer #Breastcancerresearch

The @fda.gov approved a combination of two drugs — enfortumab vedotin and an immunotherapy drug pembrolizumab, to be given before and after surgery for people w/ muscle-invasive urothelial carcinoma — a cancer that usually starts in the bladder & can also appear in other parts of the urinary system.

Excited to share our new study, the paper is out today @cp-immunity.bsky.social! Not all Treg cells are the same. We identified two Treg cell subsets with opposing functions in colorectal cancer (CRC). 1/8

🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK. Learn more: bit.ly/4iVd9Y6

(1/2) Researchers from the Sloan Kettering Institute at MSK discovered that not all regulatory T cells behave the same way in tumors. Some help fight cancer, while others protect it.

Results from #SABCS25: A trial, reported by breast cancer medical oncologist @breastcancerdoc.bsky.social, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy. bit.ly/3MGgZs6

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...

We're excited for AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @karunamdphd.bsky.social will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @theaacr.bsky.social @mskcancercenter.bsky.social #AACRearlyonset25 TODAY | 3:20 p.m. ET bit.ly/4qlOXB1

Dr. Jun Mao, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @sabcs.bsky.social . Learn more: bit.ly/4aeZAkg

#SABCS25 posters! Visit Dr. Tiffany Traina to learn about the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social ⏰ 12:30–2 p.m. CST bit.ly/4puGBqn

TODAY at the #SABCS25: Dr. Jun Mao, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @sabcs.bsky.social 🗓️: December 12 at 9 a.m. (CST)

🎉 Congratulations to MSK's Dr. Jason Lewis for being elected as a Fellow of the National Academy of Inventors, a prestigious honor recognizing individuals who have demonstrated innovation and made tangible contributions to the advancement of technology. Learn more: www.mskcc.org/news-release...

HAPPENING SOON at #SABCS25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients. @sabcs.bsky.social. 🗓️: December 11 at 1 p.m. (CST)

@breastcancerdoc.bsky.social, a breast medical oncologist at MSK, presented results from the ASCENT-07 clinical trial at the @sabcs.bsky.social. The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people... (cont.) bit.ly/4pBgRZC

Coming up at #SABCS25: Join @saratchandarlapaty.bsky.social for a session examining the evolving role of antibody-drug conjugates in #bcsm @sabcs.bsky.social @mskcancercenter.bsky.social TODAY | 1 p.m.–2:15 p.m. CST Learn more: bit.ly/4aJ8pTk

HAPPENING SOON at #SABCS25: MSK breast oncologist and early drug development specialist Dr. @breastcancerdoc.bsky.social will present results from her ASCENT-07 clinical trial for patients with HR+/HER2 metastatic #breastcancer. @sabcs.bsky.social 🗓️: December 10 at 9:30 am (CST)

#ASH25: Our collaborator María-Victoria Mateos will share results of a phase 3 study of teclistamab plus daratumumab for relapsed refractory #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @ash.hematology.org @szusmani.bsky.social TODAY | 8:45 a.m. EST Learn more: bit.ly/3MN6MKr

Dr. Heather Landau presented the results of a promising phase 1 study evaluating CAR T cell therapy for light chain #amyloidosis at #ASH25. Read more about her research: bit.ly/4rKq3fJ @ash.hematology.org @drmiguelperales.bsky.social @mskcancercenter.bsky.social

Dr. Heather Landau, a cellular therapist at MSK, recently presented findings from a phase 1 clinical trial for patients with light chain (AL) amyloidosis with at the 2025 @ash.hematology.org Annual Meeting. #ASH25 bit.ly/4aBRoKM

Next at #ASH25: #Leukemia expert @raajitrampal.bsky.social will present durable efficacy and long-term safety of pelabresib plus ruxolitinib in JAK inhibitor–naive #myelofibrosis from the phase 3 MANIFEST-2 study. @mskcancercenter.bsky.social @ash.hematology.org #leusm Learn more: bit.ly/3MnLwee

New results from a clinical trial show that giving two bispecific antibodies in combination can be effective in people with extramedullary myeloma, an especially resistant form of #multiplemyeloma.

Coming up at #ASH25: Join Dr. Andrew Intlekofer for a presentation on using enzyme hyperactivation to target oncometabolism in IDH-mutant #leukemia cells. @mskcancercenter.bsky.social @ash.hematology.org #leusm #lymsm #lymphoma Learn more: bit.ly/48G5vfs

Great work by super talented @mskcancercenter.bsky.social BMT Lab Faculty Jennifer Tsai @mskdeptofmed.bsky.social #ash25

Important collaboration with colleagues at @bristolmyerssquib.bsky.social where we validated @mskcancercenter.bsky.social Inflamix prognostic model developed by Sandeep Raj (left) in pts with LBCL treated with lisp-cel CD19 CART cell #ash25

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma @ash.hematology.org @mskcancercenter.bsky.social #ASH25 www.onclive.com/view/epcorit...

A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding #epcoritamab to #rituximab + #lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. #ASH25 Learn more: www.mskcc.org/news/new-tri...

10 questions with @mskcancercenter.bsky.social @mskdeptofmed.bsky.social Division Chief Ivan Maillard #ash25 @ash.hematology.org

Join Dr. Xiaoli Mi this morning at #ASH25 for the presentation, "CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies." #lymsm #leusm @mskcancercenter.bsky.social @ash.hematology.org Learn more: bit.ly/3MnS7VY

Congrats Molly Benson & Ross Firestone 🎉 @mskcancercenter.bsky.social @mskdeptofmed.bsky.social #ash35 #mmsm #bmstm

Check out these great posters from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social investigators #ash25

Coming up at #ASH25: @sridevirajeeve.bsky.social will present a study evaluating remote patient monitoring for outpatient step-up dosing for bispecific antibodies at a large academic center. @ash.hematology.org @mskcancercenter.bsky.social #mmsm Learn more: bit.ly/4pjLwKL

At #ASH25, Dr. Mohammad Alhomoud will present a study that determined the optimal fludarabine exposure in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide. @mskcancercenter.bsky.social @ash.hematology.org Learn more:

Coming up at #ASH25: Dr. Xin Wang will present findings from a study that compared outcome disparities between Asian and White patients with newly diagnosed acute myeloid #leukemia. @mskcancercenter.bsky.social @ash.hematology.org #leusm Learn more: bit.ly/48lX22j

At #ASH25, Dr. Kuo-Kai Chin will present a retrospective study that evaluated outcomes of patients with acute myeloid #leukemia whose cancer stopped responding to or returned after menin inhibitor treatment. #leusm @mskcancercenter.bsky.social @ash.hematology.org Learn more: bit.ly/44as0YP

#ASH25: Divyash Shah will present the results of a study assessing the comparative incidence of venous thromboembolism in patients with chemotherapy-induced thrombocytopenia treated with romiplostim. @mskcancercenter.bsky.social @ash.hematology.org Learn more:

Tomorrow morning at #ASH25, Varun Iyengar, MD, will present a study evaluating venous thromboembolism risk factors found via genomic profiling cross subtypes of B-cell #lymphoma. @mskcancercenter.bsky.social @ash.hematology.org #lymsm Learn more: bit.ly/4pucLmc

At #ASH25, join #lymphoma specialist Quinlan Sievers to learn about molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation. #lymsm @mskcancercenter.bsky.social @ash.hematology.org TODAY | 4:32 p.m. ET Learn more: bit.ly/48PRRb3

At #ASH25, join @hemejz.bsky.social to learn how the cellular pathways that allow blood to clot can contribute to #cancer growth and spread, presenting opportunities for new treatment approaches. @mskcancercenter.bsky.social @ash.hematology.org Learn more: bit.ly/3Mpu7BL

MSK is excited to be in Orlando, Florida for #ASH25! Follow along on our social channels from Dec. 6-9 for updates. @ash.hematology.org

The FDA just approved the CAR T cell therapy lisocabtagene maraleucel for adults with relapsed or refractory marginal zone #lymphoma. Congratulations to study investigator M. Lia Palomba! #lymsm @mskcancercenter.bsky.social

Join Richard Lin today at #ASH25 to learn about methods for preventing and treating age-related blood conditions, including #exercise, #nutrition, new therapies, and more. @mskcancercenter.bsky.social @ash.hematology.org Learn more: bit.ly/48EEMjz

A longitudinal study led by Dr. Maximilian Merz sheds new light on why cilta-cel yielded better response rates compared to ide-cel for those with relapsed/refractory #multiplemyeloma. @mskcancercenter.bsky.social #mmsm @szusmani.bsky.social #CARTcelltherapy

Happy #FellowMatch day! We look forward to welcoming 18 hematology/oncology fellows to @mskcancercenter.bsky.social next summer to continue our legacy of providing outstanding #cancer care. #Match2026

🚨: A clinical trial that resulted in a new @fda.gov approval, led by Dr. Yelena Janjigian, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination w/a standard-of-care chemotherapy regimen before & after surgery for people w/stomach & esophagus cancer. bit.ly/3XVQC3G

Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.

🚨 Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #PhD programs at MSK's Gerstner Sloan Kettering Graduate School of Biomedical Sciences is 12/1. Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️

Out in @bmjmedicine.bsky.social: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @mskcancercenter.bsky.social ➡️ bit.ly/48bhFOx